Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| EA5161 | ECOG-ACRIN | Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5162 | ECOG-ACRIN | Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR | Adult CIRB - Early Phase Emphasis | Available to Open | |
| EA5163 | ECOG-ACRIN | INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5181 | ECOG-ACRIN | Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5182 | ECOG-ACRIN | Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5191 | ECOG-ACRIN | A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5221 | ECOG-ACRIN | A Randomized Phase III Trial of Chemo Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6134 | ECOG-ACRIN | DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6141 | ECOG-ACRIN | Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6174 | ECOG-ACRIN | STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab, a Phase III Trial | Adult CIRB - Late Phase Emphasis | Available to Open |